Around 80% of CD8+ T cell depletion was achieved by anti-CD8 antibody when assessed at the end stage of the tumor experiment (Fig. S4 G); CD8+ T cell depletion desensitized tumors to NR-V04 treatment (Fig. S4 H), supporting the critical role of CD8+ T cells in mediating tumor suppressive effect of NR-V04. Here, CD8A is linked to neoplasm.